Please use this identifier to cite or link to this item:
http://hdl.handle.net/11054/1065
Title: | Clinical effectiveness of early posaconazole suspension pre-emptive therapy in lung transplant recipients: the Alfred's experience. |
Authors: | Wirawan, Jeong Snell, Greg I. Levvey, Bronwyn J. Westall, Glen P. Morrissey, C. Orla Ivulich, Steven Neoh, Chin Fen Slavin, Monica A. Kong, David C. M. |
Issue Date: | 2017 |
Publication Title: | The Journal of Antimicrobial Chemotherapy |
Volume: | 72 |
Issue: | 7 |
Start Page: | 2089 |
End Page: | 2092 |
Abstract: | This study describes the clinical outcomes and therapeutic drug monitoring (TDM) following posaconazole suspension pre-emptive therapy in lung transplant (LTx) recipients. This was a single-centre, retrospective cohort study evaluating posaconazole suspension pre-emptive therapy in LTx recipients between January 2009 and December 2015. Forty-two LTx recipients were prescribed posaconazole suspension pre-emptively. Aspergillus fumigatus was the most commonly isolated fungal organism. Of the patients receiving posaconazole suspension as the initial antifungal post-LTx, 93% had eradication of colonization at 6 months after commencing therapy. In contrast, only 61% had eradication of fungal colonization when posaconazole suspension was administered following initial therapy with voriconazole. Posaconazole suspension appeared to be well tolerated, although one case was curtailed following concern about abnormal liver function and another due to nausea/vomiting. TDM was performed in 37 patients. The initial median (IQR) trough plasma concentration (Cmin) following 400 mg twice-daily posaconazole suspension was 0.78 (0.46–1.19) mg/L. Doses beyond 800 mg daily did not appear to result in a higher median Cmin Early initiation of posaconazole suspension pre-emptive therapy in LTx recipients appears to be well tolerated and may potentially afford favourable clinical outcomes. |
URI: | http://hdl.handle.net/11054/1065 |
DOI: | doi.org/10.1093/jac/dkx085 |
Internal ID Number: | 01051 |
Health Subject: | ANTIFUNGAL AGENTS ASPERGILLUS FUMIGATUS DRUG MONITORING LUNG TRANSPLANTATION POSACONAZOLE RETROSPECTIVE STUDIES SUSPENSION VORICONAZOLE |
Type: | Journal Article Article |
Appears in Collections: | Research Output |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.